A DNA-repair prognostic signature for early-stage NSCLC patients, in IFCT-0002 trial of neoadjuvant chemotherapy.

Gerard Zalcman,Guenaelle Levallet,Pierre Fouret,Martine Antoine,Elisabeth Brambilla,Emmanuel Bergot,Francoise Galateau-Salle,Armelle Lavole,Elisabeth A. Quoix,Didier Debieuvre,Julien Mazieres,Denis Moro-Sibilot,Jean-Louis Pujol,Denis Braun,Michele Beau-Faller,Laurence Baudrin,Franck Morin,Virginie Westeel

Journal of Clinical Oncology（2017）

引用 1|浏览32

暂无评分

摘要

7515 Background: IFCT-0002 trial compared two perioperative CT regimens, CDDP-Gemcitabine vs.CBDCA-Paclitaxel in 528 stage I-II NSCLC patients. Paraffin-embedded post-chemo specimens were collected...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要